Neogen Investigation Notice: Levi & Korsinsky - Sep 30

The Story

Levi & Korsinsky has notified investors of a pending investigation into Neogen Corporation after an FDA warning tied to the recalled HYCOAT equine product, and $NEOG shares fell as much as 7.22% in a single session. The probe focuses on whether Neogen adequately disclosed product-quality risks to investors before the news hit the market.

Why It Matters For Your Portfolio

• Regulatory risk: An FDA warning over a recalled product has already coincided with a 7.22% intraday drop, which can increase short-term volatility for $NEOG and related veterinary suppliers.
• Legal risk: A formal investigation by Levi & Korsinsky raises the chance of plaintiff litigation or disclosures, which could pressure shares and prompt material filings to the SEC.
• Valuation signals: Available data points include 17.95%, 9.42%, 0.57%, and 50%, and analysts note there are multiple figures investors can use for valuation checks before adding exposure to $NEOG.
• Event watchlist: Expect heightened attention on company statements, FDA updates, and any legal notices that could move the stock.